STOCK TITAN
  1. Home
  2. Sec-filings
  3. CUE
  4. [ARS] Cue Biopharma, Inc. SEC Filing

[ARS] Cue Biopharma, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - Cue Biopharma, Inc.

ARS Filing - Cue Biopharma, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Cue Biopharma, Inc. (CUE)

Acceptance Date: 2026-03-16T16:01:40.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Cue Biopharma Inc

NASDAQ:CUE

View CUE Stock Overview →

CUE Rankings

#5992 Ranked by Market Cap
N/A Ranked by Dividends
#52 Top Loser

CUE Latest News

Mar 16, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Mar 9, 2026
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
Feb 17, 2026
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
Feb 12, 2026
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Dec 19, 2025
Cue Biopharma Announces Pricing of $10 Million Public Offering

CUE Latest SEC Filings

Mar 17, 2026
[S-3] Cue Biopharma, Inc. Shelf Registration Statement
Mar 16, 2026
[DEF 14A] Cue Biopharma, Inc. Definitive Proxy Statement
Mar 16, 2026
[10-K] Cue Biopharma, Inc. Files Annual Report
Mar 16, 2026
[8-K] Cue Biopharma, Inc. Reports Material Event
Mar 6, 2026
[PRE 14A] Cue Biopharma, Inc. Preliminary Proxy Statement

CUE Stock Data

25.88M
90.65M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON